Plain-English translation of NCT06254469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new brain imaging technique called -PET to see if it can predict how memory problems will progress in people with mild cognitive impairment. The scan looks for abnormal proteins in the brain that may be related to either repeated head injuries or Alzheimer's disease. Researchers want to know if this imaging can accurately predict who will experience further cognitive decline and help tell the difference between these two conditions.
Currently, doctors have limited tools to predict whether someone's memory problems will get worse over time, or to distinguish between memory loss caused by past head injuries versus Alzheimer's disease. This new imaging technique could help doctors understand what's happening in the brain and better anticipate disease progression.
You likely qualify if…
You likely don't qualify if…
You would receive a specialized brain imaging scan (PET scan) that shows protein buildup in your brain. The study includes an initial screening visit, the imaging visit, and then follow-up appointments at 1 year and 2 years to assess how your thinking and memory have changed over time. You'll also likely have cognitive testing (memory and thinking tests) and work with trained staff to evaluate your brain scan results. The entire process spans up to 2 years, with visits at regular intervals.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States